Skip to main content
Figure 2 | Critical Care

Figure 2

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Figure 2

Comparison of the proportion of patients (all coagulopathic patients as well as coagulopathic patients surviving more than 48 hours) requiring massive transfusion. Massive transfusion was defined as more than 12 red blood cell (RBC) units within 48 hours of the first dose, which equals more than 20 units of RBCs (inclusive of the 8 pre-dose units) in the placebo and recombinant activated factor VII (rFVIIa) groups.

Back to article page

Critical Care

ISSN: 1364-8535